Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.
About 12.07% of ONCT shares are held by financial institutions. STEWARD PARTNERS INVESTMENT ADVISORY, LLC is the top corporate investor, holding 15 shares valued at $8.00. A 0% stake in Oncternal Therapeutics, Inc. is owned by the company. ADVISOR GROUP HOLDINGS, INC. owns 150 shares valued at $198.00, which translates its holding of 0.01% of the stake in the company.
Among the ONCT insiders holding of 9.23% of the stake in company, SCHULER JACK W, 10 percent owner, holds the largest shares of 6.17M. HYDE JOSEPH R III, , is the second largest ONCT insider with ownership of 5.99M shares. STEINER MITCHELL SHUSTER, Chief Executive Officer, stands third with possession of 1.95M shares of that stake.
| Insiders | Designation | Shares Held |
|---|
| SCHULER JACK W | 10 percent owner | 6.17M |
| HYDE JOSEPH R III | | 5.99M |
| STEINER MITCHELL SHUSTER | Chief Executive Officer | 1.95M |
| SHANGHAI PHARMACEUTICAL (USA) INC. | 10 percent owner | 524.66K |
| PYRAMID PEAK FOUNDATION | 10 percent owner | 339.17K |
| BREITMEYER JAMES B | Chief Executive Officer | 194.29K |
| GLASS J KENNETH | director | 183.77K |
| YAZJI SALIM | Chief Medical Officer | 164.68K |
| VINCENT RICHARD G | Chief Financial Officer | 156.86K |
| SEAR TIMOTHY R G | director | 150K |
| HANOVER MARC STEVEN | Chief Executive Officer | 124.36K |
| LEAVITT CHASE C. | General Counsel/Secretary | 106.9K |
| KAUFMANN GUNNAR F. | Chief Scientific Officer | 94.73K |
| CARTER MICHAEL G | director | 71.95K |
| AKER HAZEL M | Legal Counsel | 46.99K |
| YOUNG DIANE C. | VP, Chief Medical Officer | 45.94K |
| DOGGRELL HENRY PATTON | VP, Chief Legal Officer | 43.63K |
| SHACKELFORD JASON T | Prin Fin. & Acct. Officer | 19.45K |
| KISNER DANIEL L | director | 10K |
| WILLS ROBERT JAMES | director | 10K |
| HALE DAVID F | director | 714 |
| MOSTELLER MARK EDWARD | Vice President, CFO | 0 |
| DALTON JAMES T | VP, Chief Scientific Officer | 0 |
